Viridian Therapeutics, Inc. VRDN NASDAQ

Viridian Therapeutics, Inc. (VRDN) reported total assets of $899.42M and total liabilities of $177.25M for quarter ending 2025-12-31, resulting in total equity of $722.17M.

The company held $874.65M in cash and short-term investments. Total debt stood at $50.69M, with net debt of $-161.69M. The Debt-to-Equity (D/E) ratio was 0.07 (conservative).

Current ratio is 12.65, indicating strong short-term liquidity. Interest coverage is -18.6x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (62/100) — Total assets $899.42M and equity $722.17M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.07 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.